Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma

Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma

Objective: To analyze the clinical characteristics of children with Burkitt lymphoma (BL) and to summarize the mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 (CNCL-B-NHL-2017) regimen. Methods: Clinical features of 436 BL patients who were ≤18 years old and treated wit...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 60(2022), 10 vom: 02. Okt., Seite 1011-1018
1. Verfasser: Zhang, M (VerfasserIn)
Weitere Verfasser: Wu, P, Duan, Y L, Jin, L, Yang, J, Huang, S, Liu, Y, Hu, B, Zhai, X W, Wang, H S, Fu, Y, Li, F, Yang, X M, Liu, A S, Qin, S, Yuan, X J, Dong, Y S, Liu, W, Zhou, J W, Zhang, L P, Jia, Y P, Wang, J, Qu, L J, Dai, Y P, Guan, G T, Sun, L R, Jiang, J, Liu, R, Jin, R M, Wang, Z J, Wang, X G, Zhang, B X, Chen, K L, Zhuang, S Q, Zhang, J, Zhou, C J, Gao, Z F, Zheng, M C, Zhang, Yonghong
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:Journal Article Rituximab 4F4X42SYQ6 Lactate Dehydrogenases EC 1.1.-
LEADER 01000caa a22002652c 4500
001 NLM347231276
003 DE-627
005 20250303224118.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20220429-00390  |2 doi 
028 5 2 |a pubmed25n1157.xml 
035 |a (DE-627)NLM347231276 
035 |a (NLM)36207847 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Zhang, M  |e verfasserin  |4 aut 
245 1 0 |a Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 11.10.2022 
500 |a Date Revised 11.10.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To analyze the clinical characteristics of children with Burkitt lymphoma (BL) and to summarize the mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 (CNCL-B-NHL-2017) regimen. Methods: Clinical features of 436 BL patients who were ≤18 years old and treated with the CNCL-B-NHL-2017 regimen from May 2017 to April 2021 were analyzed retrospectively. Clinical characteristics of patients at disease onset were analyzed and the therapeutic effects of patients with different clinical stages and risk groups were compared. Survival analysis was performed by Kaplan-Meier method, and Cox regression was used to identify the prognostic factors. Results: Among 436 patients, there were 368 (84.4%) males and 68 (15.6%) females, the age of disease onset was 6.0 (4.0, 9.0) years old. According to the St. Jude staging system, there were 4 patients (0.9%) with stage Ⅰ, 30 patients (6.9%) with stage Ⅱ, 217 patients (49.8%) with stage Ⅲ, and 185 patients (42.4%) with stage Ⅳ. All patients were stratified into following risk groups: group A (n=1, 0.2%), group B1 (n=46, 10.6%), group B2 (n=19, 4.4%), group C1 (n=285, 65.4%), group C2 (n=85, 19.5%). Sixty-three patients (14.4%) were treated with chemotherapy only and 373 patients (85.6%) were treated with chemotherapy combined with rituximab. Twenty-one patients (4.8%) suffered from progressive disease, 3 patients (0.7%) relapsed, and 13 patients (3.0%) died of treatment-related complications. The follow-up time of all patients was 24.0 (13.0, 35.0) months, the 2-year event free survival (EFS) rate of all patients was (90.9±1.4) %. The 2-year EFS rates of group A, B1, B2, C1 and C2 were 100.0%, 100.0%, (94.7±5.1) %, (90.7±1.7) % and (85.9±4.0) %, respectively. The 2-year EFS rates was higher in group A, B1, and B2 than those in group C1 (χ2=4.16, P=0.041) and group C2 (χ2=7.21, P=0.007). The 2-year EFS rates of the patients treated with chemotherapy alone and those treated with chemotherapy combined with rituximab were (79.3±5.1)% and (92.9±1.4)% (χ2=14.23, P<0.001) respectively. Multivariate analysis showed that stage Ⅳ (including leukemia stage), serum lactate dehydrogenase (LDH)>4-fold normal value, and with residual tumor in the mid-term evaluation were risk factors for poor prognosis (HR=1.38,1.23,8.52,95%CI 1.05-1.82,1.05-1.43,3.96-18.30). Conclusions: The CNCL-B-NHL-2017 regimen show significant effect in the treatment of pediatric BL. The combination of rituximab improve the efficacy further 
650 4 |a Journal Article 
650 7 |a Rituximab  |2 NLM 
650 7 |a 4F4X42SYQ6  |2 NLM 
650 7 |a Lactate Dehydrogenases  |2 NLM 
650 7 |a EC 1.1.-  |2 NLM 
700 1 |a Wu, P  |e verfasserin  |4 aut 
700 1 |a Duan, Y L  |e verfasserin  |4 aut 
700 1 |a Jin, L  |e verfasserin  |4 aut 
700 1 |a Yang, J  |e verfasserin  |4 aut 
700 1 |a Huang, S  |e verfasserin  |4 aut 
700 1 |a Liu, Y  |e verfasserin  |4 aut 
700 1 |a Hu, B  |e verfasserin  |4 aut 
700 1 |a Zhai, X W  |e verfasserin  |4 aut 
700 1 |a Wang, H S  |e verfasserin  |4 aut 
700 1 |a Fu, Y  |e verfasserin  |4 aut 
700 1 |a Li, F  |e verfasserin  |4 aut 
700 1 |a Yang, X M  |e verfasserin  |4 aut 
700 1 |a Liu, A S  |e verfasserin  |4 aut 
700 1 |a Qin, S  |e verfasserin  |4 aut 
700 1 |a Yuan, X J  |e verfasserin  |4 aut 
700 1 |a Dong, Y S  |e verfasserin  |4 aut 
700 1 |a Liu, W  |e verfasserin  |4 aut 
700 1 |a Zhou, J W  |e verfasserin  |4 aut 
700 1 |a Zhang, L P  |e verfasserin  |4 aut 
700 1 |a Jia, Y P  |e verfasserin  |4 aut 
700 1 |a Wang, J  |e verfasserin  |4 aut 
700 1 |a Qu, L J  |e verfasserin  |4 aut 
700 1 |a Dai, Y P  |e verfasserin  |4 aut 
700 1 |a Guan, G T  |e verfasserin  |4 aut 
700 1 |a Sun, L R  |e verfasserin  |4 aut 
700 1 |a Jiang, J  |e verfasserin  |4 aut 
700 1 |a Liu, R  |e verfasserin  |4 aut 
700 1 |a Jin, R M  |e verfasserin  |4 aut 
700 1 |a Wang, Z J  |e verfasserin  |4 aut 
700 1 |a Wang, X G  |e verfasserin  |4 aut 
700 1 |a Zhang, B X  |e verfasserin  |4 aut 
700 1 |a Chen, K L  |e verfasserin  |4 aut 
700 1 |a Zhuang, S Q  |e verfasserin  |4 aut 
700 1 |a Zhang, J  |e verfasserin  |4 aut 
700 1 |a Zhou, C J  |e verfasserin  |4 aut 
700 1 |a Gao, Z F  |e verfasserin  |4 aut 
700 1 |a Zheng, M C  |e verfasserin  |4 aut 
700 1 |a Zhang, Yonghong  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 60(2022), 10 vom: 02. Okt., Seite 1011-1018  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnas 
773 1 8 |g volume:60  |g year:2022  |g number:10  |g day:02  |g month:10  |g pages:1011-1018 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20220429-00390  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 60  |j 2022  |e 10  |b 02  |c 10  |h 1011-1018